![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VALEANT SIGNS AGREEMENT WITH ALLERGAN
VALEANT SIGNS AGREEMENT WITH ALLERGAN
June 27, 2005
Valeant Pharmaceuticals announced June 22 that it has signed an agreement with Allergan to be the exclusive distributor of Allergan's Botox product in Hungary and Poland. Valeant has a strong presence in these regions and will begin distributing Botox in Hungary in July and in Poland in September. Detailed terms of the agreement were not disclosed. "Valeant is a company focused on neurology, infectious disease and dermatology with commercial strength in Central and Eastern Europe," Valeant President and CEO Timothy Tyson said.
Genetic Engineering News
(http://www.genengnews.com/news/bnitem.aspx?name=554641XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct